Abstract: A display panel and a display device are provided, the display panel includes a base substrate and a touch wire including a first sub-portion and a second sub-portion, a main surface of the base substrate is a first surface; the second sub-portion includes a first height portion and a second height portion, a height of the first height portion relative to the first surface is smaller than a height of the second height portion relative to the first surface, line widths of respective positions of the first height portion are inversely proportional to heights of the respective positions of the first height portion relative to the first surface, and line widths of respective positions of at least part of the second height portion are proportional to heights of the respective positions of the at least part of the second height portion relative to the first surface.

Abstract: A display substrate and a display apparatus. The display substrate has a display region (AA) and an opening (O) located in the display region (AA). The opening (O) penetrates the display substrate, and the display substrate comprises a base substrate (BS), a driving circuit layer, a light-emitting device layer, an encapsulation layer and a touch layer (TL). The driving circuit layer is arranged on the base substrate (BS), and comprises a first signal line (L1) at least partially surrounding the opening (O). The light-emitting device layer is arranged on the side of the driving circuit layer distant from the base substrate (BS). The encapsulation layer is arranged on the side of the light-emitting device layer distant from the base substrate (BS).

Abstract: The present invention provides use of a multi-target protein kinase inhibitor compound A or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating leukemia, and provides a method for treating acute myeloid leukemia, especially acute myeloid leukemia with FLT3 mutation, with compound A. In clinical trials, compound A has certain efficacies both on acute myeloid leukemia with FLT3-ITD mutation and/or FLT3-TKD mutation, and on DEK-CAN positive acute myeloid leukemia with FLT3-ITD mutation. Patients with relapsed and/or refractory acute myeloid leukemia who have failed treatment previously with Type II FLT3 inhibitors (e.g., sorafenib) can still clinically benefit from the treatment with compound A.